New Stock News | Puqi Pharmaceutical submits application to Hong Kong Stock Exchange

According to the disclosure by the Hong Kong Stock Exchange on January 21, Beijing Puqi Pharmaceutical Technology Co., Ltd. (referred to as Puqi Medicine) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC SEC and CMBC CAPITAL as joint sponsors. The prospectus shows that Puqi Medicine is a biotechnology company focused on the field of immune inflammation, dedicated to becoming a leader in targeted therapy delivery. Since its establishment in 2016, the company has focused on innovative original design and precise local delivery as its core capabilities, deeply cultivating the field of chronic inflammatory disease treatment, aiming to provide innovative solutions that combine efficacy, safety, and long-term patient satisfaction. Puqi Medicine has developed its core product PG-011 (Pumeixitini), which has two dosage forms, including Pumeixitini gel for atopic dermatitis and Pumeixitini nasal spray for allergic rhinitis. The company also has a diversified portfolio of candidate products, including PG-033 tablets for pruritus, PG-018 tablets for autoimmune kidney disease, and PG040 eye drops for glaucoma.